Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

被引:15
|
作者
Leach, Amanda J. [1 ]
Morris, Peter S. [1 ,2 ]
Mackenzie, Grant [1 ]
McDonnell, Joseph [1 ]
Balloch, Anne [3 ]
Carapetis, Jonathan [1 ,2 ]
Tang, Mimi [3 ]
机构
[1] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia
[2] Flinders Univ S Australia, NT Clin Sch, Darwin, NT, Australia
[3] Murdoch Childrens Res Inst, Melbourne, Vic, Australia
关键词
immunogenicity; 16; serotypes; pneumococcal vaccines; high-risk population;
D O I
10.1016/j.vaccine.2008.05.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2,4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001. Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA. Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were > 1.95 mu g/ml and at least 89% of infants had IgG > 035 mu g/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was > 035 mu g/ml for more than 96% infants (> 1.3 mu g/ml for at least 70%), and IgG to non-7PCV serotypes was > 035 mu g/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%). Conclusion: 7PCV and 23PPV are immunogenic in this population. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3885 / 3891
页数:7
相关论文
共 50 条
  • [31] Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes
    Ciruela, Pilar
    Soldevila, Nuria
    Hernandez, Sergi
    Selva, Laura
    de Sevilla, Mariona F.
    Jose Garcia-Garcia, Juan
    Moraga, Fernando
    Maria Planes, Ana
    Munoz-Almagro, Carmen
    Dominguez, Angela
    VACCINE, 2013, 31 (06) : 960 - 966
  • [32] AIDS VACCINES - TRIALS SET IN HIGH-RISK POPULATIONS
    COHEN, J
    SCIENCE, 1992, 258 (5089) : 1729 - 1729
  • [33] Adjuvant polypeptide vaccines for high-risk uveal melanoma
    Gaughan, Elizabeth Mary
    Lucchesi, Nicholas
    Jin, Ruyun
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Should the new pneumococcal vaccine be used in high-risk children?
    Finn, A
    Booy, R
    Moxon, R
    Sharland, M
    Heath, P
    ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (01) : 18 - 21
  • [35] IDENTIFICATION AND VACCINATION OF PATIENTS AT HIGH-RISK FOR THE DEVELOPMENT OF PNEUMOCOCCAL PNEUMONIA
    ALGUIRE, PC
    HOPPE, RB
    CLINICAL RESEARCH, 1983, 31 (02): : A636 - A636
  • [36] Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
    Papadatou, Ioanna
    Spoulou, Vana
    CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (05) : 388 - 395
  • [37] Pneumococcal Disease in High-Risk Adults in Lebanon: Expert Opinion
    Bizri, Abdulrahman
    Ibrahim, Ahmad
    Dagher, Elissar
    Matar, Madonna
    Mohammed, Malek
    Bitar, Nizar
    Atallah, Paola
    Moghnieh, Rima
    Musharrafieh, Umayya
    Aoun-Bacha, Zeina
    VACCINES, 2022, 10 (10)
  • [38] Accelerated schedule of hepatitis B vaccination in high-risk youth
    Wilkinson, SE
    Morath, M
    Bennett, DL
    Burgess, MA
    Isaacs, D
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1996, 32 (01) : 60 - 62
  • [39] HIGH-RISK POPULATION SCREENING FOR MUCOPOLYSACCHARIDOSES
    Cobos, Nieves P.
    Gal, A.
    Lukacs, Z.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S87 - S87
  • [40] Preterm Birth in a High-Risk Population
    Munn, D.
    Ross, S.
    Crabbe, R.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2016, 56 : 49 - 49